Clinical Trials Corner

Dear Readers,

The Clinical Trials Corner of the Bladder Cancer journal is a section devoted towards highlighting ongoing trials or recently completed trials in urothelial cancer. Our hope is to encourage accrual for ongoing trials and to educate readers on the results of completed trials. If you feel that you would like to draw attention to a specific trial, please feel free to email us at: pkagarwal@uchicago.edu and/or cns9006@med.cornell.edu.

Sincerely,

Piyush K. Agarwal Cora N. Sternberg
Piyush K. Agarwal, MD Cora N. Sternberg, MD, FACP
Associate Editor, Bladder Cancer Associate Editor, Bladder Cancer
Director, Bladder Cancer Program Clinical Director, Englander Institute of Precision Medicine
University of Chicago Medicine Weill Cornell Medicine
Chicago, IL, USA New York, NY, USA

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

Status: 
Closed
Sponsor: 
Eli Lilly and Company
Participating centers: 
123 locations: United States (several centers), Australia, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Korea, Netherlands, Poland, Romania, Russia, Spain, Taiwan, Turkey, United Kingdom
Accrual: 
expected 524
Study Design: 
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy. Patient must have had disease progression while on a platinum containing regimen in the first-line setting or within 14 months after completing the first-line platinum regimen. Participants who received treatment with one immune checkpoint inhibitor regimen are eligible (for example PD-1, PDL1, or CTLA4) and may have a longer interval since prior platinum-containing therapy (≤24 months). Patients are excluded who have received prior systemic taxane therapy.
Rationale: 
Ramucirumab is a monoclonal antibody that acts to inhibit vascular endothelial growth factor (VEGF); ramucirumab acts on VEGF-2. Adding this new antiangiogenic agent ramucirumab to docetaxel chemotherapy has shown promising results as a second-line therapy in advanced or metastatic urothelial carcinoma. At the Genitourinary Cancers Symposium (GUCS) in 2015. Petrylak et al. presented a planned interim analysis of a phase 2 randomized trial that showed that the combination regimen significantly increased progression-free survival (22 weeks) as compared with docetaxel alone (10.4 weeks). The ramucirumab plus docetaxel combination conferred a statistically significant progression-free survival improvement of greater than 11.5 weeks and reduced the risk of disease progression by 61%. Results were consistent across pre-specified subgroups and it showed an acceptable safety profile. Ramucirumab has been approved for use in gastric cancer and non–small cell lung cancer after it was shown to prolong overall survival in phase 3 second-line studies.

A Study of Atezolizumab Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Status: 
Closed
Sponsor: 
Roche/Genentech
Participating centers: 
United States (several centers), Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Serbia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom
Accrual: 
expected 767
Study Design: 
Phase III, randomized trial comparing atezolizumab (anti-PD-L1 antibody) with chemotherapy in locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy
Rationale: 
Powles et al. reported a 26% overall response rate with atezolizumab in patients with metastatic urothelial cancer in a Phase I study. Recently, more data in heavily pretreated patients from the IMvigor210 study have been presented by Rosenberg et al. at the European Cancer Congress (Vienna, September 2015) meeting and at the Genitourinary Cancers Symposium (GUCS) in January 2016. IMvigor 210 enrolled an all-comer population independent of PD-L1 immunohistochemistry (IC) status (n=311). There was a 27% response rate in patients with IC2/3 status, 10% with IC1 and 9% with IC0. Therefore, the IMvigor211 trial is trying to establish the merits of using atezolizumab in the second-line setting after failing platinum-based chemotherapy.
Comments: 
It will be interesting to see how the responses and more importantly overall survival of second-line chemotherapy will compare with second-line immunotherapy, that has been shown to improve OS in other tumor types.

Pages